AVGO vs PFE: Which Is the Better Buy?

Side-by-side comparison of Broadcom Inc. and Pfizer Inc. — fair value, conviction, valuation metrics, and QuantHub research signals. Updated 2026-04-11.
Broadcom Inc. · Technology
$371.59
-49.9% upside to fair value
Grade C High Quality
VS
Pfizer Inc. · Healthcare
$26.91
+30.1% upside to fair value
Med Conviction Grade B+
QuantHub Verdict
PFE has more upside to fair value (+30.1%). PFE trades at a lower forward P/E (9.5x). These are model outputs — not personalized investment advice. See all research →
Valuation & Fundamentals
Metric AVGO PFE
Current Price $371.59 $26.91
Fair Value Estimate $186.35 $35.00
Upside to Fair Value -49.9% +30.1%
Market Cap $1,761.8B $153.0B
Forward P/E 70.7x 9.5x
EV / EBITDA 46.7x 13.8x
Price / Sales 25.9x 2.4x
Price / FCF 61.1x 16.8x
Revenue Growth YoY +7.2% -1.6%
Gross Margin 67.1% 70.3%
Operating Margin 40.9% 24.7%
Return on Equity 32.9% 9.0%
Dividend Yield 0% 6.4%
FCF Yield 1.64% 5.9%
Analyst Consensus Strong Buy Hold
Investment Thesis
AVGO — Broadcom Inc.
Broadcom Inc. is a leading technology company specializing in semiconductors and infrastructure software, with a strong competitive moat driven by scale, diversification, and aggressive M&A under CEO Hock E. Tan. The company has demonstrated robust revenue growth, particularly in semiconductor solutions and infrastructure software segments, with a 25% year-over-year increase recently and a five-y…
PFE — Pfizer Inc.
Pfizer remains the world's largest traditional pharmaceutical company by non-COVID revenue, generating $62.6B in 2025 sales across oncology, cardiovascular, immunology, and vaccines. The stock trades at a P/S of 2.44x, still well below the 5-year median of 3.10x, driven by post-COVID revenue normalization, a $17-18B patent cliff spanning 2026-2028, and $61.6B in acquisition-related debt from Seag…
Accumulation Zones
Metric AVGO PFE
Zone Low $139.76 $25.00
Zone High $158.40 $29.00
In Buy Zone? No Yes
← AVGO Research    PFE Research →    All Research